PPBT Purple Biotech Ltd Final Profit

Corporate emblem and logo of Purple Biotech Ltd. (PPBT)

The success of Purple Biotech (PPBT) is based on the efficacy of targeted agents against solid tumors and survival data. On GURU.Markets, the company's actual profit demonstrates a trend where -0.03 is the current level of the indicator. The high productivity of the R&D pipeline with candidates CM24 and NT219, combined with a proprietary antibody, creates a closed patent perimeter, tying medical centers to long-term therapy protocols.

PPBT (Purple Biotech) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Purple Biotech Ltd. (PPBT)

- stock value and consensus price forecast:
Market Price Kitov Pharma|PPBT - Price Target Chart
- market capitalization data:
Market Value Kitov Pharma|PPBT - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Purple Biotech|PPBT - Book Capitalization|Market Cap to Net Assets Ratio purple-biotech.com|PPBT - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Purple Biotech|PPBT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Purple Biotech Ltd|PPBT - Company Aggregate Debts|Debts to Book Value Kitov Pharma|PPBT - Company Long-Term Debt|Current Liabilities Purple Biotech|Quick Ratio purple-biotech.com
- net income and valuation multiples indicators:
PPBT - Company Net Income
Fundamental valuation:PPBT Kitov Pharma
Manufactured product of Purple Biotech Ltd

This indicator measures the actual daily business return, stripping the financial result of market noise to assess the real viability of the enterprise. An analysis of Purple Biotech (PPBT) net profit margins allows investors to compare returns against the company's ESG compliance costs, including energy-saving upgrades and the safe disposal of chemicals in oncology laboratories.

Main competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Company Net Income Accuray Incorporated (ARAY)|SLS: Profit After Tax|Actuate Therapeutics - Net Income|Net Profit Citius Oncology Inc. CTOR|HURA - Company Net Income|Final Profit TARA (Protara Tx)|Fate Therapeutics, Inc. (FATE) - Company Net Income|Profit After Tax WHWK (Aadi Bioscience)|Company Net Income TScan Therapeutics Inc|Company Net Income CSBR|Net Profit XBIT|CVM - Company Net Income|OS Therapies Incorporated - Net Income|Final Profit RADX|Artiva - Net Profit|ANL: Company Net Income|VERU: Net Profit|TPST - Net Financial Result|Company Net Income Xilio Therapeutics Inc|Company Net Income Enochian BioSciences RENB|Net Income MURA (Mural Oncology plc)|Profit After Payment of Taxes KAPA|Net Profit OKUR (OnKure Therapeutics)|CytoMed Therapeutics Ltd (GDTC) - Company Net Income|Curis Corp - Net Profit|Apollomics, Inc. (APLM) - Net Income|THAR: Net Profit|Advanced Biomed - Final Profit|Company Net Income Genprex, Inc|Calidi Bio - Profit After Tax|Company Net Income Sunshine Biopharma (SBFM)|XBIO: Profit After Tax|Net Profit SLRX (Salarius Pharmaceuticals, Inc.)|American Oncology Network Inc - Company Net Income|BGNE: Net Income|Checkpoint Therapeutics Inc - Profit After Payment of Taxes|ELEV: Net Profit|Net Income iCAD|IKNA (Ikena Oncology Inc.) - Net Profit|Net Profit Notable Labs Ltd|Company Net Income Viracta Therapeutics (VIRX)|MorphoSys Corporation - Company Profit|Net Profit NAYA (NAYA Biosciences)|AAPGV - Net Income